Both peak and late aggregation are capable of identifying patients at risk for atherothrombotic events

• References

• 1 Steinhubl SR, Berger PB, Mann III JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
• 2 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
• 3 Sibbing D, Braun S, Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
• 4 Marcucci R, Gori AM, Paniccia R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242.
• 5 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
• 6 Gurbel PA, Bliden KP, Guyer K. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
• 7 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
• 8 Geisler T, Kapp M, Gohring-Frischholz K. et al. Residual platelet activity is increased in Clopidogreland ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008; 94: 743-747.
• 9 Breet NJ, van Werkum JW, Bouman HJ. et al. Comparison between platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
• 10 Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535-544.
• 11 Siller-Matula J, Schror K, Wojta J. et al. Thienopyri-dines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
• 12 Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
• 13 Gachet C, Hechler B, Leon C. et al. Activation of ADP receptors and platelet function. Thromb Haemost 1997; 78: 271-275.
• 14 Labarthe B, Theroux P, Angioi M. et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638-645.
• 15 Lordkipanidze M, Pharand C, Palisaitis DA. et al. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 2009; 124: 546-553.
• 16 van Werkum JW, Kleibeuker M, Mieremet N. et al. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. J Thromb Haemost 2007; 05: 884-886.
• 17 Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123: 172-183.
• 18 Moffat KA, Ledford-Kraemer MR, Nichols WL. et al. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005; 93: 549-553.
• 19 Breddin HK. Can platelet aggregometry be standardized?. Platelets 2005; 16: 151-158.
• 20 Guidelines on platelet function testing.. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1988; 41: 1322-1330.
• 21 The Clinical and Laboratory Standards Institute. Available at: http://www.clsi.org. 2010
• 22 Cattaneo M, Zighetti LM, Lombardi R. et al. Molecular basis of defective signal transduction in platelet P2Y12 receptor a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-1983.
• 23 Remijn JA, Wu YP, Jeninga EH. et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686-691.
• 24 Bonello L, Tantry US, Marcucci R. et al. Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. J Am Coll Cardiol 2010; 56: 919-933.